Caribou Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Caribou Biosciences, Inc. (CRBU) announces its participation in key investor conferences to discuss its CRISPR genome-editing technology. The company will be present at Citi's 2024 Virtual Oncology Leadership Summit, Leerink Global Biopharma Conference, Barclays Global Healthcare Conference, and H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. Webcasts will be accessible on Caribou's website for 30 days post-event.

BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences:

• Citi's 2024 Virtual Oncology Leadership Summit
  February 21, 2024, fireside chat at 12:00 pm EST
  

• Leerink Global Biopharma Conference
  March 12, 2024, fireside chat at 1:40 pm EDT
  

• Barclays Global Healthcare Conference
  March 13, 2024
  

• H.C. Wainwright 2^nd Annual Cell Therapy Virtual Conference
  March 26, 2024, fireside chat at 11:30 am EDT
  

For more information and links to available webcasts, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for 30 days after the events.

About Caribou’s novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve antitumor activity. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T and CAR-NK platforms as readily available treatments for patients with hematologic malignancies and solid tumors. Follow us @CaribouBio and visit www.cariboubio.com.

Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com

Media:
Peggy Vorwald, PhD
media@cariboubio.com

FAQ

When is Caribou Biosciences, Inc. participating in Citi's 2024 Virtual Oncology Leadership Summit?

Caribou Biosciences, Inc. is participating in Citi's 2024 Virtual Oncology Leadership Summit on February 21, 2024, with a fireside chat at 12:00 pm EST.

What conferences will Caribou Biosciences, Inc. be attending in March 2024?

Caribou Biosciences, Inc. will be attending Leerink Global Biopharma Conference on March 12, 2024, Barclays Global Healthcare Conference on March 13, 2024, and H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26, 2024.

Where can one find more information and webcasts related to Caribou Biosciences, Inc.'s participation in investor conferences?

For more information and links to available webcasts, visit the Events page on Caribou Biosciences, Inc.'s website. Webcasts will be available on the website for 30 days after the events.